Comparative Outcome Analysis of Lenvatinib Versus Sorafenib for Recurrence of Hepatocellular Carcinoma After Liver Transplantation
Our findings suggest lenvatinib is a valuable treatment option for patients with HCC recurrence after LT.
Authors
- Christian Tibor Josef Magyar
- Grainne M. O’Kane (ORCID: https://orcid.org/0000-0002-8690-403X)
- Sophie Feng (ORCID: https://orcid.org/0000-0001-7710-5888)
- Elmar Jaeckel (ORCID: https://orcid.org/0000-0003-4108-7192)
- Laia Aceituno (ORCID: https://orcid.org/0000-0001-5414-2408)
- Woo Jin Choi (ORCID: https://orcid.org/0000-0003-4456-6500)
- Zhihao Li (ORCID: https://orcid.org/0000-0002-5654-7043)
- Nazia Selzner (ORCID: https://orcid.org/0000-0002-9435-2597)
- Sheron Perera (ORCID: https://orcid.org/0000-0001-8048-0611)
- Luckshi Rajendran (ORCID: https://orcid.org/0000-0002-2716-7121)
- Eric X. Chen (ORCID: https://orcid.org/0000-0002-4581-8848)
- Jennifer J. Knox (ORCID: https://orcid.org/0000-0003-3474-6647)
- Fahad Almugbel
- Arndt Vogel (ORCID: https://orcid.org/0000-0003-0560-5538)
- Robert C. Grant (ORCID: https://orcid.org/0000-0002-9821-0377)
- Nazanin Falla-Rad
- Gonzalo Sapisochin
Institutions
- University College Dublin (IE)
- University of Bern (CH)
- Sunnybrook Health Science Centre (CA)
- University Health Network (CA)
- University of Toronto (CA)
- King Faisal Specialist Hospital & Research Centre (SA)
- University Hospital of Bern (CH)
- Toronto General Hospital (CA)
- Princess Margaret Cancer Centre (CA)
- Medizinische Hochschule Hannover (DE)
- St. Vincent's University Hospital (IE)
- Redcliffe Hospital (AU)
Publication Details
- Journal
- Transplantation
- Published
- 2024-11-06
- DOI
- https://doi.org/10.1097/tp.0000000000005240
- Citations
- 10
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 3.69